Unguided Electronic Cigarette Use Beneficial for Smoking Cessation

TUESDAY, Aug. 29, 2023 (HealthDay News) -- Electronic cigarettes (e-cigarettes) are beneficial for smoking cessation in adult smokers with varied motivation for smoking cessation, according to a study published online Aug. 15 in eClinicalMedicine.
Matthew J. Carpenter, Ph.D., from the Medical University of South Carolina in Charleston, and colleagues examined the naturalistic uptake, use, and impact of e-cigarettes among adults who may or may not want to stop smoking in a randomized, controlled clinical trial involving adult smokers. Participants across the motivational spectrum were randomly assigned to receive a free four-week supply of flavored, tank-style e-cigarettes or not (427 and 211, respectively). The e-cigarette group participants received a battery and device with up to 30 prefilled tanks and were provided with minimal instructions for use.
The researchers found that e-cigarette uptake was robust, with about 70 percent of participants using the product and average usage exceeding four days per week during the initial 30-day period. In an intent-to-treat approach with missing data imputed as smoking, almost all behavioral outcomes favored the e-cigarette group compared with the control group, including point prevalence abstinence at six months (odds ratio [OR], 1.8; 95 percent confidence interval [CI], 1.0 to 3.1), cumulative incidence of 24-hour quit attempts (OR, 1.5; 95 percent CI, 1.0 to 2.2), and having reduced smoking by at least 50 percent since baseline (OR, 1.8; 95 percent CI, 1.2 to 2.7). Under an alternative imputation, results were similar.
"It's rarely the case that you're proven correct for almost everything that you predicted," Carpenter said in a statement. "No matter how we looked at it, those who got the e-cigarette product demonstrated greater abstinence and reduced harm as compared to those who didn't get it."
Several authors disclosed ties to the biopharmaceutical industry; one author serves as paid expert witness in litigation filed against the tobacco industry.
Related Posts
Newer Diabetes Meds Might Not Work as Well in Black Patients
FRIDAY, Sept. 22, 2023 (HealthDay News) – New research suggests some newer...
Sanofi sigue a Lilly y Novo Nordisk, y reduce los precios de la insulina
VIERNES, 17 de marzo de 2023 (HealthDay News) -- Sanofi Inc. se convirtió el...
Se propagan los casos de unas peligrosas infecciones fúngicas resistentes a los medicamentos
MARTES, 21 de marzo de 2023 (HealthDay News) -- La popular serie de HBO, "The...